SMAD4/DPC4 expression and prognosis in human colorectal cancer

Martin Isaksson-Mettävainio1, Richard Palmqvist, Johan Forssell

  • 1Department of Medical Biosciences, Umeå University, Sweden.

Anticancer Research
|June 3, 2006
PubMed
Abstract

Insights

Loss of SMAD4 protein expression in colorectal cancer (CRC) indicates a poor prognosis. This finding highlights SMAD4's role in CRC development and patient outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Colorectal cancer (CRC) is a prevalent malignancy in Western nations.
  • Loss of genetic material on chromosome 18, housing the SMAD4 gene, is a key event in CRC.
  • SMAD4 is a critical mediator in the TGF-beta signaling pathway, with its inactivation observed in CRC.

Purpose of the Study:

  • To investigate the clinical significance of SMAD4 protein expression in colorectal cancer.
  • To determine the association between SMAD4 expression levels and patient prognosis.

Main Methods:

  • Immunohistochemical analysis of SMAD4 protein expression in 86 CRC tissue samples.
  • Correlation of SMAD4 expression with clinicopathological variables and patient survival data.

Main Results:

  • Loss of nuclear SMAD4 protein expression was detected in 9.3% of CRC cases studied.
  • This loss of expression significantly correlated with poorer patient prognosis in both univariate and multivariate analyses (p=0.034 and p=0.028, respectively).

Conclusions:

  • Reduced nuclear SMAD4 protein expression is a recurring event in a subset of colorectal cancers.
  • The loss of SMAD4 expression serves as a significant indicator of poor prognosis in CRC patients.